Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ALDH2
REST API REST API
Homo sapiens
ALDH2 is differentially expressed in 328 experiments: 102 organism parts: liver, placenta, ... (100 more);, 201 disease states: normal, glioblastoma, ... (199 more);, 109 cell types 514 cell lines 40 compound treatments and 71 other conditions.
Orthologs Aldh2 (Mus musculus)   ALDH2_BOVIN (Bos taurus)   aldh2b (Danio rerio)   BX510999.1 (Danio rerio)   E1BT93_CHICK (Gallus gallus)   aldh2a (Danio rerio)   ALD5 (Saccharomyces cerevisiae)   ALDH2_RAT (Rattus norvegicus)   ALD4 (Saccharomyces cerevisiae)   ALD6 (Saccharomyces cerevisiae)   CABZ01032488.1 (Danio rerio)   Aldh (Drosophila melanogaster)   aldh2 (Xenopus laevis)   LOC611711 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term oxidoreductase activity, oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor, metabolic process, aldehyde dehydrogenase [NAD(P)+] activity, mitochondrial matrix, synaptic transmission, neurotransmitter biosynthetic process, ethanol oxidation, electron carrier activity, carbohydrate metabolic process, alcohol metabolic process, aldehyde dehydrogenase (NAD) activity, mitochondrion, xenobiotic metabolic process, oxidation-reduction process
InterPro Term Aldehyde_DH_dom
UniProt Accession P05091, Q9UN17, B4YAH7, B0LUF9, B0LUG0, B0LUG2, E7EUE5, F8VSB0, F8VXI5, F8W0A9
Gene-Disease Assocation ALCOHOL SENSITIVITY, ACUTE, ALDEHYDE DEHYDROGENASE 2 FAMILY; ALDH2
Search EB-eye ENSG00000111275
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, ... (30 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (44 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
A549
2
E-GEOD-3202, E-GEOD-6013
BT20
2
E-MTAB-37, E-MTAB-62
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1143
2
E-MTAB-37, E-MTAB-62
508 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (52 experiments)

Factor Value U/D Experiments
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
macrophage
2
E-GEOD-3982, E-GEOD-5099
mononuclear cell
2
E-GEOD-6053, E-MEXP-66
CD8+ T cell
2
3
E-AFMX-5, E-MTAB-25, E-GEOD-6740, E-TABM-145, E-GEOD-19069 ... (5 experiments)
CD14+ monocyte
1
2
E-AFMX-5, E-MEXP-1600, E-TABM-145
103 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-TABM-15, E-GEOD-3678, ... (66 experiments)

Factor Value U/D Experiments
benign prostatic hyperplasia
3
E-MEXP-2034, E-MEXP-1243, E-GEOD-5377
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
obesity
2
E-GEOD-2508, E-MTAB-62
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
Duchenne muscular dystrophy
2
E-GEOD-1004, E-GEOD-3307
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
195 more value(s).


Compound treatment

studied in E-GEOD-5741, E-GEOD-5824, E-TABM-868, E-GEOD-3140, E-MEXP-1958, ... (26 experiments)

Factor Value U/D Experiments
none
5
10
E-MEXP-1958, E-MEXP-1601, E-GEOD-5741, E-GEOD-412, E-GEOD-2803, ... (15 experiments)
lipopolysaccharide
1
2
E-MEXP-1958, E-TABM-868, E-GEOD-3140
PGE2
1
E-MEXP-1230
unknown
1
E-GEOD-7307
BCR/FGFR1
1
E-GEOD-15811
AMP
1
E-MEXP-2285
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-1140, E-MEXP-1251, E-GEOD-19246, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-GEOD-1638, E-MEXP-2359, E-GEOD-2666, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-2509, E-GEOD-22148, E-TABM-147, ... (8 experiments)

double amplification
studied in E-GEOD-22601

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-MEXP-1996, E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-22278, E-GEOD-10315, E-GEOD-837, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-5764, E-TABM-740, E-GEOD-2466, ... (35 experiments)

Infection
studied in E-GEOD-12108, E-MEXP-561

Karyotype
studied in E-GEOD-22056

Light
studied in E-GEOD-1725

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-AFMX-1, E-GEOD-426, E-TABM-84 ... (5 experiments)

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (9 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2508, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-1295 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-GEOD-2748

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, ... (6 experiments)

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-4922

Processing time: 0.355 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM